Primary Aldosteronism and Continuous Blood Pressure Monitoring

A recent study published in Science Translational Medicine on September 6, 2026, reveals that primary aldosteronism, a potentially curable hormone disorder, may drive millions of high blood pressure cases. Researchers from the University of Bristol and international partners utilized a wearable skin monitor called U-Rhythm to track hormone patterns continuously over 24 hours among 60 patients. The author highlights that standard single-time-point blood tests frequently miss the condition due to natural hormone fluctuations and hidden nocturnal surges. The investigation demonstrates that aldosterone levels repeatedly climb and fall, with distinct hormone bursts occurring during sleep that routine clinical appointments completely overlook. The essence of the research points toward a paradigm shift in diagnosing secondary hypertension by moving away from isolated blood draws toward continuous 24-hour monitoring of hormone rhythms. This breakthrough approach captures subtle disease patterns, particularly in patients where hormone overproduction originates in a single adrenal gland. Practical application involves redesigning clinical pathways for hypertension screening to incorporate dynamic measurement tools. Early detection of primary aldosteronism opens opportunities for targeted surgical interventions or effective medical treatments, ultimately reducing preventable cardiovascular events like heart disease and strokes.